ALKSNMSHealthcare·Drug Manufacturers - Specialty & Generic#11 in industry

Alkermes plc

Reports in 8d· 2026-05-05

+0.6% · 90d

$33.73

+0.41 (+1.25%)

News

(2)

April 2026

Apr 6, 20263 weeks agoDEF 14AHealthcare

Alkermes plc. — DEF 14A Filing

ALKSAlkermes plc.

# 🧾 What This Document Is This is a **Definitive Proxy Statement (DEF 14A)** filed with the SEC. Its purpose is to give shareholders the information they need to vote at the upcoming **2026 Annual General Meeting**. Think of it as the official agenda and guidebook for the meeting, explaining what

Read summaryView on SEC EDGAR

Apr 6, 20263 weeks agoDEFA14AHealthcare

Alkermes plc. — DEFA14A Filing

ALKSAlkermes plc.

# 🧾 What This Document Is This is a **DEFA14A**, which stands for "Definitive Additional Material" related to a proxy statement. Think of it as a "last call" reminder and voting guide for shareholders before a big vote. It’s not the full proxy statement itself, but a supplemental notice summarizin

Read summaryView on SEC EDGAR

Key Data

Market Cap$5.62B

Open$33.31

Prev Close$33.31

Day Range$32.84 – $34.29

52W Range$25.17 – $36.48

Volume846,813

P/E (TTM)23.58

EPS$1.43

Dividend Yield—

Beta0.39

Profit Margin16.37%

Revenue Growth-10.60%

Price Target$44.24(+31.2%)

Next Earnings2026-05-05(8d)

Analyst Ratings

Strong Buy18 analysts

Buy 15Hold 3Sell 0

About

Alkermes plc, a biopharmaceutical company, engages in the research, development, and commercialization of pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. The company has a portfolio of proprietary commercial products for the treatment of opioid dependence, alcohol dependence, schizophrenia, bipolar I, and a pipeline of clinical and preclinical product candidates in development for neurological disorders. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; ARISTADA INITIO for the treatment of schizophrenia in adults; VIVITROL for the treatment of alcohol and prevention of opioid dependence; LYBALVI, an oral atypical antipsychotic drug candidate for the treatment of adults with schizophrenia and bipolar I disorder; and LUMRYZ, an extended-release oral suspension product for the treatment of cataplexy or EDS in pediatric patients. The company also offers proprietary technology platforms to third parties to enable them to develop, commercialize, and manufacture products. It has collaboration agreements primarily with Janssen Pharmaceutica N.V., Janssen Pharmaceutica Inc, and Janssen Pharmaceutica International. Alkermes plc was founded in 1987 and is headquartered in Dublin, Ireland.

Healthcare · Drug Manufacturers - Specialty & Generic

2,050 employees

www.alkermes.com